• Background: Apolipoprotein E (ApoE) polymorphism has been shown to influence serum lipid parameters and ApoE levels in both healthy subjects and hemodialysis (HD) patients. Conversely, ApoE concentration significantly affects serum lipid levels in the general population, independently of ApoE polymorphism, by modulating lipoprotein production, lipolytic conversion, and receptor-mediated clearance. Therefore, studying the effect of ApoE polymorphism on serum lipid levels without taking into account ApoE levels could lead to confounding results. However, such a combined study has not been performed in HD patients to date. Methods: Three hundred one patients without diabetes on long-term maintenance HD therapy and 200 matched healthy subjects were studied. Determination of levels of fasting serum ApoE and other lipid parameters, as well as common ApoE genotypes, was performed in all subjects. Results: HD patients had a significantly lower prevalence of the ⑀4 allele and greater levels of ApoE compared with the control population. ApoE2 allele carriers had significantly lower levels of ApoB and serum total, low-density lipoprotein, and non-high-density lipoprotein cholesterol, as well as increased ApoE levels. When ApoE levels were included in analysis, ApoE levels themselves were proven to be important determinants of serum lipid levels, whereas the effect of ApoE polymorphism became more pronounced. The combination of these 2 factors explains a much greater percentage of the variation in the studied parameters than each factor alone. Conclusion: For the first time, our study provides data to support that ApoE concentration in combination with the ApoE polymorphism significantly influences serum lipid parameters in HD patients. Am J Kidney Dis 44:300-308.
A POLIPOPROTEIN E (ApoE), a 34,200-kd protein consisting of 299 amino acids, has a major role in the metabolism of lipids and lipoproteins. 1 It is found in chylomicrons, chylomicron remnants, very low-density lipoproteins (VLDLs), VLDL remnants, and a subfraction of the high-density lipoproteins (HDLs), serving as a ligand for their receptor-mediated catabolism through the low-density lipoprotein (LDL) receptor (ApoB100/E) and other ApoE receptors. 2 The ApoE gene, located on chromosome 19q13.2, has 3 common alleles, ⑀2, ⑀3, and ⑀4, coding for the 3 main isoforms of the ApoE protein: E2 (Arg 158 7Cys), E3 (parent isoform), and E4 (Cys 112 7Arg). Therefore, there are 6 common ApoE genotypes: ApoE3/3, ApoE4/4, ApoE2/2, ApoE3/2, ApoE4/2, and ApoE4/3. 3 ApoE isoforms differ in their receptor-binding ability; ApoE4 has the maximum binding capacity, whereas ApoE2 is defective in its binding ability to the ApoE receptors. 3 The different functional properties of the ApoE isoforms result in a characteristic pattern of differences in plasma lipid and apolipoprotein levels, with lower plasma total cholesterol (TC), LDL cholesterol (LDL-C), and ApoB levels in ApoE2 carriers than in ApoE3/3 subjects, and with greater levels in ApoE4 carriers. 4 No other single genomic polymorphism has been identified with such a large contribution (up to 17%) to the general interindividual variability in plasma cholesterol concentrations.
Furthermore, serum ApoE concentration significantly modulates lipoprotein levels in an isoform-independent manner by its effects on clearance rate, lipolytic conversion, and VLDL production. 5 For example, ApoE levels accounted for 34.6% of the triglyceride (TG) variance, independently of ApoE polymorphisms, in the Stanislas cohort study, 6 whereas ApoE concentration was independently associated with levels of TC, TG, ApoB, and ApoA-I in another study. 7 Notably, ApoE concentration was positively related to TG levels in the group with coronary artery disease, but not in healthy subjects in the previously mentioned study. 7 Additionally, ApoE polymorphism significantly influences serum ApoE levels in a gene-dose manner, being the greatest in E2 carriers and the lowest in E4 carriers. 8 Consequently, the association between ApoE polymorphism and serum lipid parameters may be confounded or masked by ApoE concentration. ApoE concentration, together with ApoE polymorphism, can explain a much greater percentage of cholesterol and TG level variability than ApoE polymorphism alone. 9 Conversely, atherosclerotic vascular disease is the leading cause of death among patients with end-stage renal disease (ESRD), whereas abnormal lipoprotein metabolism has an important role in the acceleration of atherosclerosis in these patients. [10] [11] [12] In this context, ApoE polymorphism has been found to significantly influence serum lipid profiles in patients undergoing longterm hemodialysis (HD) therapy, [13] [14] [15] [16] thus affecting the risk for atherosclerosis in this population. 17 ApoE also exerts a major influence on the pathogenesis and progression of a variety of renal diseases 18 (recently reviewed in 19 ). However, data are limited for serum ApoE concentrations in HD patients, whereas, to the best of our knowledge, there are no studies examining the combined effect of both serum ApoE level and ApoE polymorphism on serum lipid parameters in these patients. Thus, we undertook the present study to test the hypothesis that serum ApoE concentration could influence the effect of ApoE polymorphism on lipoprotein metabolism in HD patients.
METHODS

Study Populations
Our study population consisted of 301 patients on longterm maintenance HD therapy for at least 6 months before their inclusion in the study. The HD schedule was 4 hours 3 times per week using cuprophane or hemophane hollowfiber dialyzers and acetate or bicarbonate dialysate containing 2 g/L of glucose. Adequacy of dialytic treatment was evaluated by means of the Kt/V ratio, which ranged from 1.2 to 1.4, whereas residual renal function estimated by the average of residual creatinine and urea clearances was almost negligible (Ͻ5.0 mL/min). Renal diagnoses were chronic glomerulonephritis in 59 patients, hypertensive nephropathy in 62 patients, chronic pyelonephritis in 35 patients, polycystic kidney disease in 30 patients, and obstructive uropathy in 36 patients, whereas it remained unknown in the remaining 79 patients. Patients with a known family history of primary dyslipidemia, excessive alcohol consumption, diabetes mellitus (fasting serum glucose Ͼ126 mg/dL [Ͼ6.93 mmol/L]), obesity (body mass index [BMI] Ͼ30 kg/m 2 ), liver disease, systemic illness, thyroid disorders, or any other metabolic or endocrine disorders were excluded from the study. Patients were administered no other medication except low-molecular-weight heparins, erythropoietin, polyvitamins, calcitriol, iron, phosphate binders other than sevelamer hydrochloride, angiotensin-converting enzyme inhibitors, and calcium channel blockers. Patients administered statins or other lipid-lowering drugs or any other medication known to affect serum lipid levels (eg, ␤-blockers) also were excluded from the study.
Furthermore, 200 healthy individuals from the same region matched for age, sex, and smoking habits with the HD patients also were studied. These subjects were consecutive, healthy, unrelated individuals who underwent a regular checkup in our outpatient internal medicine clinic. None of these individuals was administered drugs affecting lipid profile or renal function. Smoking habit is defined as smoking currently.
All participants gave informed consent for genetic analysis, and the study protocol was approved by the ethics committee of our university hospital. In all participants, blood samples were obtained after a 14-hour overnight fast for genotype detection, as well as for determination of serum laboratory parameters. In HD patients, fasting blood samples were obtained immediately before the first dialytic session of the week. Blood samples were allowed to clot, then were centrifuged for 30 minutes (3,600g). Serum was separated and stored at Ϫ80°C for measurement of lipids and apolipoproteins.
Analytical Methods
Concentrations of TC and TG were determined enzymatically on the Olympus AU600 clinical chemistry analyzer (Olympus Diagnostica, Hamburg, Germany). HDL cholesterol (HDL-C) was determined in supernatant after precipitation of the ApoB-containing lipoproteins with dextran sulfateMg ϩϩ (Sigma Diagnostics, St Louis, MO). LDL-C was calculated using the Friedewald formula if fasting TG levels were less than 400 mg/dL (Ͻ4.52 mmol/L), 20 whereas non-HDL-C was calculated using the following equation: non-HDL-C ϭ TC Ϫ HDL-C. ApoA-I, B, and E and lipoprotein (a) (Lp[a]) were measured using a Behring Nephelometer BN100 using reagents (antibodies and calibrators) from Dade Behring Holding Gmbh (Liederbach, Germany). ApoA-I and ApoB assays were calibrated according to the International Federation of Clinical Chemistry standards.
ApoE Genotyping
DNA was extracted from whole-blood specimens according to standard procedures. ApoE genotyping was performed as described by Hixson and Vernier. 21 Polymerase chain reaction was used to amplify a 244-bp sequence of the ApoE gene, including the 2 polymorphic sites. Polymerase chain reaction products then were digested with the restriction enzyme HhaI, and the different genotypes were detected after electrophoresis on 8% nondenaturing polyacrylamide gels, treated with ethidium bromide, and visualized in UV radiation. Subjects were classified as ApoE2 carriers if they had the ApoE2/2 or ApoE2/3 genotype; ApoE3 carriers, if they had the ApoE3/3 genotype; and ApoE4 carriers, if they had the ApoE4/3 or ApoE4/4 genotype. Finally, ApoE4/E2 patients were excluded from analysis because of their small number (n ϭ 3) and the difficulty classifying these individuals because of the opposite effect of the ApoE2 and ApoE4 alleles on serum lipid levels.
Statistical Analysis
Statistical analysis was performed using Statistica 6.0 statistical software (StatSoft Inc, Tulsa, OK). Chi-square test was used to compare gene frequencies, whereas Student's t-test for independent samples and Mann-Whitney U test were used to test differences in parametric and nonparametric data between the 2 study populations, respectively. The effect of the ApoE gene polymorphism on laboratory parameters was tested using 1-way analysis of variance (ANOVA), followed by the least significance difference test (in case of significant effects) for multiple pairwise comparisons, except for serum TG, ApoE, and lipoprotein(a) (Lp[a]) levels, for which Kruskal-Wallis ANOVA median test was used, followed by the Mann-Whitney U test for pairwise comparisons. Adjustment of mean levels of serum lipid parameters for age, sex, BMI, smoking, duration of HD therapy, and serum ApoE levels was made by means of analysis of covariance (ANCOVA). Because of the skewed distribution, logarithmic transformation of TG, ApoE, and Lp(a) levels was applied. Multiple linear regression analysis was performed to test the overall effect on lipid parameters of ApoE polymorphism and other factors found to significantly correlate with the studied parameters in univariate analysis (age, sex, BMI, current smoking, and duration of dialysis treatment; model A). To further investigate the effect of ApoE concentration on the studied parameters, we added ApoE concentration to model A (model B). We used the standard method for simultaneous entering of all parameters into the linear regression models. The total percentage of the explained variability of each studied parameter by the independent variables included in the multiple linear regression models is defined as R 2 ϫ 100. Table 1 lists clinical and laboratory characteristics of the study population. HD patients had a decreased BMI; decreased levels of serum TC, LDL-C, HDL-C, and non-HDL-C; and elevated levels of TG compared with healthy subjects. Notably, mean LDL-C concentration in our HD population was as low as 104 mg/dL (2.69 mmol/ L), although no patient was administered statins or other hypolipidemic drugs. Selection criteria (exclusion of patients with obesity, diabetes, or family history of primary dyslipidemia) may account for these low LDL-C levels. Furthermore, HD patients showed increased serum ApoE levels (40.8 Ϯ 18.7 versus 36.3 Ϯ 8.4 mg/L; P ϭ 0.024) and elevated Lp(a) levels, as well as reduced serum ApoA-I and ApoB levels, compared with the control population. Conversely, there were no differences in age, sex ratio, smoking habits, or fasting serum glucose levels between the 2 groups. Table 2 lists frequencies of ApoE genotypes and ApoE alleles in the study population. ApoE gene frequencies in both groups were in HardyWeinberg equilibrium. ApoE allele frequencies of our control population did not differ from those reported in other south European populations. 9 Interestingly, our HD patients showed a significantly reduced frequency of ApoE4-carrying genotypes and ⑀4 allele (7.5% versus 14.0% in the control population; P ϭ 0.0000 by chisquare test). Table 3 lists effects of the ApoE polymorphism on serum lipid parameters in HD patients Values expressed as mean Ϯ SD, except for Lp(a) and TG, expressed as median (range). Values were compared using t-test for independent samples, except for ApoE, Lp(a), and TG, for which Mann-Whitney U test was used. To convert serum glucose in mg/dL to mmol/L, multiply by 0.055; TC, LDL-C, HDL-C, and non-HDL-C in mg/dL to mmol/L, multiply by 0.0259; TG in mg/dL to mmol/L, multiply by 0.0113.
RESULTS
Abbreviation: NS, not significant.
by unadjusted ANOVA test. The 3 allele groups were well matched with respect to age, sex ratio, BMI, duration of dialysis treatment, and fasting serum glucose level. ApoE2 carriers had significantly lower levels of TC, LDL-C, non-HDL-C, ApoB, and TG compared with both ApoE3/3 patients and ApoE4 carriers. Furthermore, the ⑀2 allele resulted in significantly elevated serum ApoE levels than the ⑀3 and ⑀4 alleles (50.4 Ϯ 21.8 versus 39.5 Ϯ 13.2 versus 33.3 Ϯ 11.7 mg/dL, respectively; P ϭ 0.0000). Conversely, ApoE4 carriers had the greatest levels of TC, LDL-C, non-HDL-C, apoB, and TG, as well as the lowest value for serum ApoE, whereas concentrations of HDL-C, ApoA-I, and Lp(a) were not different among the allele groups. Causes of renal disease in our ApoE2/E2 homozygotes were hypertensive nephropathy (1 patient), chronic pyelonephritis (1 patient), polycystic renal disease (1 patient), or unknown (2 patients). Notably, the cholesterol-and TG-lowering effect of the ⑀2 allele became more significant when ApoE2/E2 homozygotes were excluded from analysis (data not shown). Table 4 lists results of multiple linear regression analysis taking into account ApoE alleles and other factors known to affect serum lipid parameters in HD patients, with ApoE concentra- NOTE. The 3 patients with the ApoE2/4 genotype were excluded. Values are expressed as mean Ϯ SD, except for Lp(a) and TG, expressed as median (range). Values were compared using unadjusted 1-way ANOVA with the least significant difference test for pairwise comparisons in case of significant results, except for ApoE, Lp(a), and TG, for which Kruskal-Wallis ANOVA median test was used with the Mann-Whitney U test for pairwise comparisons in case of significant results. To convert serum glucose in mg/dL to mmol/L, multiply by 0.055; TC, LDL-C, HDL-C, and non-HDL-C in mg/dL to mmol/L, multiply by 0.0259; TG in mg/dL to mmol/L, multiply by 0.0113.
tion not included (model A) or included (model B) in analysis. ApoE alleles, independently of other factors, significantly influenced serum levels of TC, TG, LDL-C, non-HDL-C, and ApoB (model A).
However, when ApoE concentration entered the analysis (model B), 3 important observations were made: First, the association of ApoE alleles with the studied parameters became statistically more powerful. Alternatively, results of the ANCOVA test, with sex, age, BMI, smoking, duration of HD therapy, and ApoE levels treated as covariates (adjusted ANOVA), showed a statistically more powerful effect of ApoE alleles on serum lipid parameters (data not shown). Second, ApoE levels themselves had a great impact on the variation in the studied parameters independently of the ApoE polymorphism, and third, there was a significant increase in the percentage of the explained variance in the studied parameters (from 7% to 30% in TC, from 30% to 51.7% in LogTG, from 7% to 14.9% in LDL-C, from 4% to 27% in non-HDL-C, and from 4.9% to 22% in ApoB). Conversely, only ApoE level, but not ApoE polymorphism, affected serum HDL-C and ApoA-I levels (Table 4) , whereas neither ApoE level nor ApoE polymorphism influenced Lp(a) concentration (data not shown). Furthermore, ApoE polymorphism, but not sex, age, BMI, smoking, or duration of HD therapy, significantly influenced serum ApoE levels in HD patients (Table 5) .
Finally, similar results were obtained in our healthy population regarding the effect of the ApoE polymorphism on serum lipid parameters. Moreover, the entry of ApoE concentration into the analysis resulted in a significant increase in the proportion of explained variance in the studied parameters, similar to that observed in HD patients (TC, from 5% to 31%; LogTG, from 37% to 54%; and ApoB, from 6% to 26.3%; data not shown).
DISCUSSION
Our study provides for the first time data on the combined effect of both ApoE polymorphism and serum ApoE level on serum lipid parameters in HD patients. The addition of serum ApoE concentration into the analysis results in more pronounced differences in lipid parameters among ApoE allele carriers, whereas a significant in- crease in percentage of explained variability of the studied parameters is observed. ApoE2 carriers had the lowest levels of TC, LDL-C, non-HDL-C, and ApoB in our study. This cholesterol-lowering effect of the ⑀2 allele can be seen in almost all studies involving healthy subjects 4, 9 or HD patients. [13] [14] [15] [16] Because of the failure of the ApoE2 isoform to bind effectively to the LDL and ApoE receptors, less cholesterol from the chylomicrons, the VLDL and their remnants, enters the hepatocytes, resulting in upregulation of LDL receptors, which in turns decreases serum ApoB-containing lipoproteins. 3 Moreover, LDL clearance probably is enhanced because of the greater affinity of LDL particles for the LDL receptor compared with remnant lipoproteins carrying the defective ApoE2. 5 Conversely, the ApoE4-induced increase in TC and LDL-C levels is attributed to an increase in intestinal absorption of dietary cholesterol 22 and downregulation of LDL receptors on the surface of hepatic cells. The latter results from increased delivery of cholesterol to hepatic cells owing to the enhanced interaction of ApoE4-containing remnants and ApoE receptors. Furthermore, ApoE genotype can influence the location of ApoE in lipoproteins, with the E4 isoform preferentially located in VLDL, and E3 and E2 isoforms, in HDL. 23 A significant effect of ApoE polymorphism on serum TG level also was noted regardless of ApoE level; ApoE2 carriers had the lowest and E4 carriers the highest levels, whereas this interaction became more profound when ApoE2/E2 homozygotes were excluded. Conflicting results concerning the relation of TG level and the ApoE polymorphism in the general population are observed in the literature. A meta-analysis documented a significant association between ApoE2 and ApoE4 and greater TG levels compared with ApoE3/E3 subjects. 24 In studies involving HD patients, ApoE polymorphism was either not associated with serum TG levels 13, 15 or there was an association among ApoE2/E2, ApoE4/E3, and ApoE4/E4 genotypes with greater TG levels, 14 as well as between ApoE4/E3 and greater TG levels. 16 Because the ApoE4 isoform is preferentially located in VLDL, 23 it could influence VLDL metabolism and therefore TG levels. 6 Conversely, no effect of ApoE polymorphisms on serum HDL-C levels was found, in agreement with other studies, 13, 14, 16 although the ⑀4 allele was associated with decreased HDL-C levels in 1 study. 15 Interestingly, 4 of 5 ApoE2/E2 homozygotes presented with a lipoprotein profile resembling type III hyperlipoproteinemia, as described. Both nephrotic syndrome and renal failure have been described to induce type III hyperlipoproteinemia in ApoE2/E2 homozygotes. 25, 26 Moreover, no ApoE2/E2 homozygote had evidence of nephrotic syndrome. Therefore, renal failure per se could have induced the type III hyperlipoproteinemia-like dyslipidemia in these patients.
Furthermore, no effect of ApoE polymorphism on serum ApoA-I level was observed in our population, in accordance with other studies. 14, 15 Additionally, increased serum Lp(a) levels were noticed in HD patients, in agreement with our previous observations. 27 Despite results of 1 study showing that ApoE polymorphism affects serum Lp(a) levels in healthy individuals, 28 we, along with others, 13 failed to confirm such an association in HD patients.
Serum ApoE levels were increased in HD patients compared with healthy controls, and this increase seems to be an additional feature of dyslipidemia in patients with renal failure. 29 Serum ApoE levels were the greatest in ApoE2/E2 homozygotes and decreased in the order of E2/ 2 Ͼ E2/3 Ͼ E3/3 Ͼ E4/3 Ͼ E4/4, in keeping with other studies of the general population 8, 9 and HD patients. 14,15 This association is highly important and indicates that ApoE locus is a major determinant of serum ApoE levels in HD patients (Table 4) . Reduced ApoE clearance caused by defective binding to ApoE receptors in ApoE2 carriers seems to be the main mechanism explaining the elevated ApoE levels in these patients.
Serum ApoE concentration has been shown to significantly influence serum lipoprotein metabolism independently and perhaps more significantly than ApoE polymorphisms in a number of ways. [5] [6] [7] [8] [9] First, ApoE directly stimulates hepatic VLDL and TG production in an isoform-independent manner. 30 Second, ApoE can inhibit lipoprotein lipase-mediated lipolysis of TG-rich lipoproteins, possibly by displacing or masking ApoC-II, which is the necessary cofactor for the lipoprotein lipase activity. 31 Finally, ApoE concentration can modulate the clearance of VLDL particles through modification of the receptorbinding properties of VLDL, in addition to the ApoE-specific isoform effect. 32 It seems there is an optimal level for serum ApoE in maintaining normolipidemia; in cases of excess ApoE levels, lipid-increasing effects of inhibited lipolysis and increased VLDL production could offset the benefits of increased lipoprotein clearance rate, resulting in hyperlipidemia. 5 Given these significant effects of ApoE concentration in lipoprotein metabolism, it is no surprise to see that the combination of both ApoE level and polymorphism explains a greater percentage of cholesterol and TG level variability than the ApoE polymorphism alone. 9 Examining the combination of these 2 factors in serum lipid levels is crucial because ApoE polymorphism also determines ApoE levels, as discussed, which may lead to confounding results. Although 4 studies examined the effect of ApoE polymorphism on serum lipid levels in HD patients, 12-15 no study to date has taken into account ApoE levels. In our study, the involvement of ApoE levels in analysis of the association between ApoE polymorphism and serum lipid levels in HD patients (Tables 4 and 5) showed that: (1) ApoE concentration itself is a major determinant of serum lipid levels and relates positively with levels of TC (␤ ϭ 0.506), LDL-C (␤ ϭ 0.29), HDL-C (␤ ϭ 0.462), non-HDL-C (␤ ϭ 0.29), TG (␤ ϭ 0.47), ApoB (␤ ϭ 0.36), and ApoA-I (␤ ϭ 0.19); (2) when ApoE levels are taken into account, ApoE polymorphism-lipid interactions become more significant; and (3) a much greater percentage of the studied parameters could be explained.
Conversely, our results regarding the combined impact of ApoE polymorphism and ApoE concentration on serum lipid parameters in our healthy subjects are in agreement with those previously reported in other healthy populations, 6, 7, 9 as well as those observed in our HD patients. Therefore, the presence of ESRD or the HD procedure per se does not seem to modify the relationship between ApoE concentration-polymorphism and serum lipid variability. However, the increased levels of serum ApoE found in uremic patients may contribute partially to the pathogenesis of some uremic lipid abnormalities (eg, hypertriglyceridemia).
Finally, we found a decreased frequency of the ⑀4 allele in our HD population compared with age-and sex-matched controls from the same region. One possible explanation is that the ⑀4 allele may be a protective factor against deterioration in renal function and progression to ESRD. This is in keeping with studies that showed a protective effect of the ApoE4 allele on deterioration in renal function in patients with type 2 diabetes 33,34 and on acute renal impairment in postbypass surgical patients, 35 as well as with 1 study that showed better renal function in ApoE4 kidney transplant recipients 36 and with our data showing a significantly lower creatinine concentration in ApoE4 healthy individuals compared with E3 and E2 carriers (0.88 Ϯ 0.11 mg/dL [77.8 Ϯ 9.7 mol/L] versus 0.92 Ϯ 0.13 mg/dL [81.3 Ϯ 11.5 mol/L] versus 1.04Ϯ 0.13 mg/dL [91.9 Ϯ 11.5 mol/L], respectively; P ϭ 0.0077). 37 Alternatively, the decreased frequency of the ApoE4 allele and ApoE4/E3 and E4/4 genotypes in our HD patients could be attributed to a greater percentage of early deaths in ApoE4 allele carriers compared with non-ApoE4 allele carriers. A low prevalence of the ApoE4 allele has been shown in a group of nonagenarians, presumably because the ApoE4 allele increases the susceptibility to death associated with coronary artery disease. 38 It should be mentioned that our control subjects and HD patients were well matched with respect to age (Table 1) . However, HD patients die prematurely because of atherosclerotic vascular disease, whereas the ApoE4 allele has been associated with increased risk for atherosclerosis in this population. 17, 39 Therefore, the possible association between ApoE4 allele and premature death may be seen earlier in HD patients compared with the healthy population and may account for the decreased frequency of the ApoE4 allele in our HD population.
In conclusion, our study provides for the first time evidence that ApoE concentration in conjunction with the ApoE polymorphism significantly affects serum lipid parameters in HD patients. Additional studies are needed to elucidate the clinical usefulness of measuring ApoE levels in HD patients and the association, if any, between serum ApoE levels and atherosclerosis in these patients. nary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients. 
